Tenaya Therapeutics
TNYA
76 hedge funds and large institutions have $127M invested in Tenaya Therapeutics in 2023 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 32 increasing their positions, 13 reducing their positions, and 14 closing their positions.
2,425% more call options, than puts
Call options by funds: $101K | Put options by funds: $4K
146% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 13
1.97% more ownership
Funds ownership: 71.26% → 73.23% (+2%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4% less funds holding
Funds holding: 79 → 76 (-3)
21% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 14
55% less capital invested
Capital invested by funds: $280M → $127M (-$153M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$4.57M |
| 2 |
BlackRock
New York
|
+$4.38M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$2.73M |
| 4 |
Millennium Management
New York
|
+$1.67M |
| 5 |
Renaissance Technologies
New York
|
+$1.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$7.47M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$3.52M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$2.76M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.38M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$494K |
TNYA Hedge Fund Activity: Q3 2023 in Review
76 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Tenaya Therapeutics (TNYA) for Q3 2023, worth a combined $127M — down 55% from $280M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of TNYA and 11 opened new positions — a net loss of 3 holders — while 13 trimmed existing stakes and 32 added.
The largest buyer was Citadel Advisors, adding an estimated $4.57M. The largest seller was T. Rowe Price Investment Management, exiting entirely with an estimated $7.47M sold.
- 76 institutional investors held Tenaya Therapeutics (TNYA) as of Q3 2023, down from 79 in Q2 2023.
- Funds reported $127M of Tenaya Therapeutics stock for Q3 2023, down 55% quarter-over-quarter.
- 11 funds opened new Tenaya Therapeutics positions in Q3 2023 and 14 closed out, a net change of -3 holders.
- The largest Tenaya Therapeutics buyer in Q3 2023 was Citadel Advisors, an estimated $4.57M added.
- The largest Tenaya Therapeutics seller in Q3 2023 was T. Rowe Price Investment Management, an estimated $7.47M sold.
Based on aggregated 13F filings for Q3 2023.